

5. W1937-01

COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR OF TETRAHYDROPYRIDINS AND ACETYLCHOLINESTERASE INHIBITING AGENTS, FOR TREATING SENILE DEMENTIA SUCH AS ALZHEIMER DEMENTIA

Patent number: WO9925363

Publication date: 1999-05-27

Inventor: TERRANOVA JEAN-PAUL (FR); MAFFRAND JEAN-PIERRE (FR); SOUBRIE PHILIPPE (FR)

Applicant: TERRANOVA JEAN PAUL (FR); SANOFI SA (FR); MAFFRAND JEAN PIERRE (FR); SOUBRIE PHILIPPE (FR)

Classification:

- **international:** A61K31/645; A61K31/445

- **european:** A61K31/645; A61K31/445

Application number: WO1998FR02384 19981109

Priority number(s): FR19970014322 19971114; FR19970014324 19971114

Also published as:

- EP1030671 (A1)
- OA11464 (A)
- CA2309966 (A1)
- TR200001262T (T2)
- EE4235 (B1)

[more >>](#)

Cited documents:

- WO9701536
- US5453428
- EP0458696
- WO9627380
- XP002074849

Abstract of WO9925363

The invention concerns a pharmaceutical composition containing as active principles: a constituent (a) selected between 1-(2-napht-2-yethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin and a compound (I) in which: Y represents -CH- or -N-; R1 represents hydrogen, a halogen, a hydroxyl, a CF₃, a (C₃-C₄)alkyl or (C₁-C₄)alkoxyl group; R2 represents hydrogen, a halogen, a hydroxyl, a CF₃, (C₃-C₄)alkyl or (C₁-C₄)alkoxyl group; R3 and R4 represent each hydrogen or a (C₁-C₄)alkyl; X represents (a) a (C₃-C₆)alkyl; a (C₃-C₆)alkoxyl; a (C₃-C₇)carboxyalkyl; a (C₁-C₄)alkoxycarbonyl(C₃-C₆)-alkyl; a (C₃-C₇)carboxyalkoxyl; or a (C₁-C₄)alkoxycarbonyl(C₃-C₆)alkoxyl; (b) a radical selected among a (C₃-C₇)cycloalkyl, (C₃-C₇)cycloalkyloxy, (C₃-C₇)cycloalkylmethyl, (C₃-C₇)cycloalkylamino and cyclohexenyl, said radical capable of being substituted by a halogen, hydroxy, (C₁-C₄)alkoxy, carboxy, (C₁-C₄)alkoxycarbonyl, amino, mono- or di-(C₁-C₄)alkyamino or (c) a group selected among phenyl, phenoxy, phenylamino, N-(C₁-C₃)alkyl-phenyl-amino, phenylmethyl, phenylethyl, p-henylcarbonyl, phenylthio, phenylsulphonyl, phenylsulphinyl and styryl, said group capable of being mono- or polysubstituted on the phenyl group by a halogen, CF₃, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, cyano, amino, mono- or di-(C₁-C₄)alkylamino, (C₁-C₄)acylamino, carboxy, (C₁-C₄)alkoxycarbonyl, aminocarbonyl, mono- or di-(C₁-C₄)alkylaminocarbonyl, amino(C₁-C₄)alkyl, hydroxy(C₁-C₄)alkyl, or halogeno(C₁-C₄)alkyl; optionally in the form of one of its pharmaceutically acceptable salts; and an constituent (b) active in the symptomatic treatment of DAT, optionally in the form of one of its pharmaceutically acceptable salts, provided that when constituent (a) is other than 1-(2napht-2-yethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin or one of its pharmaceutically acceptable salts, the constituent (b) is an acetylcholinesterase inhibiting agent.

Data supplied from the esp@cenet database - Worldwide